Wed, Aug 20, 2014, 3:29 PM EDT - U.S. Markets close in 31 mins.


% | $
Quotes you view appear here for quick access.

Merrimack Pharmaceuticals, Inc. (MACK) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • crkenmore crkenmore Sep 26, 2012 4:07 PM Flag

    Reason For the Decline Yesterday


    Your comments are helpful. As a 13 year former CEO of a technology company, I can echo sentiment that selling does not necessarily represent any lack of confidence in the company but rather the desire to realize insider liquidity. Two key questions: Can the market absorb an increase in tradable shares of 14.3 million to 78.1 million without triggering a precipitous drop in share price; Will company performance against milestones be sufficient to offset the share float overhang?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Boogins_00 what is your business with Mack?
      Sounds like you are working for them!
      Your comments are indeed helpful and educational.

      • 1 Reply to lydia_a_s
      • Sorry if I sound so biased but I'm just a long term holder of the stock(8 years) and know this group pretty well. I have recommended Merrimack to many people over many years, and will continue to. I should say first of all that there are never any guarantees in drug development, but I believe Merrimack has some of the best---if not the best---technology in drug development today. OK, so I really am biased.

        They use a unique approach that combines biology and engineering to understand an entire aberrant growth pathway in a cell(cancer) and then codify it into computer models. They have been developing this system, called network biology and pioneered at Harvard and MIT, for over ten years. It's pretty mature now and has produced a string of products and product candidates that would be the envy of a company many times their size.

        The rubber hits the road over the next year. In a week we'll see the Phase I data in multiple resistant cancers at ESMO(European Society for Medical Oncology), and then in the first half of next year we'll see the results of the first Phase II trials in breast and lung cancer. If their platform is validated via these trials, then I think the size of the float will become irrelevant. The potential here is vast, and this is an ambitious group. They abhor the 'me too' approach so prevalent in the drug industry today.

        This is classic 'high risk / high reward' investing. Any long term investor in this space has seen many a promising technology appear and fail, so don't kid yourself about the risks. I personally believe that their approach is insightful and rational, and has a decent shot at success.

6.67-0.18(-2.63%)3:29 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.